PennyTrader.com Presents Today’s Midday Stock Report: LDSI, GNOM, ANTH
Equities are hovering just beneath the unchanged line as they start the week on a negative note. The S&P 500 is down 0.2%.
Looking at the early sector performance, defensive stocks are outperforming. Health care, utilities, and consumer staples are all up near 0.1%. Meanwhile, materials, industrials and consumer discretionary stocks are all lower in the early going.
Office Depot (ODP 2.78, +0.31) is continuing its recent rally. Shares of the office supply retailer are higher by 12.6% after Starboard confirmed a 13.3% stake in the company. The fund sent a letter to the Chief Executive Officer and the Board of Directors justifying their belief that ODP stock is deeply undervalued.
LDSI – Trade Alert
Up 39.13% in morning trading to $.0031 with 25M shares traded
Life Design Station International, Inc. is a music-inspired corporation. The Company empowers artists, producers and other music professionals to reach millions of potential customers. Life Design Station International, through its Internet-based division, develops and directs an innovative global social platform allowing artists from the U.S. and the world to interface collaboratively in order to promote, produce and sell their musical artistry. LDSI’s Backstage Vibe™ provides a leading-edge, secure and user-friendly environment for the sale, distribution and securing of world talent from one source. Life Design Station International (OTC Pinks: LDSI) today announced successfully launched its innovative social music platform Backstage Vibe™ over the weekend.
To Read Full Story go to: http://www.pennytrader.com/
********************
GNOM – News Alert
Up 14.23% in morning trading to $3.05 with 3.5M shares traded
Through its pioneering sequencing-as-a-service model, Complete provides the most accurate whole human genome sequencing available today. The ease of use and power of Complete’s advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Complete Genomics, Inc. (GNOM) (”Complete”) today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete’s announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of its technology.
To Read Full Story go to: http://www.pennytrader.com/
********************
ANTH – News Alert
Up 14.22% in morning trading to $1.06 with 3M shares traded
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. Anthera Pharmaceuticals, Inc. (ANTH) today provided an update on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies. Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.
To Read Full Story go to: http://www.pennytrader.com/
********************
To Follow PennyTrader on Twitter: http://twitter.com/pennytrader
To Join Our Facebook Page: http://www.facebook.com/PennyTrader2
PennyTrader.com, PO Box 791, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@PennyTrader.com.This email address is being protected from spam bots, you need Javascript enabled to view it
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on PennyTrader.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
Leave a Comment